Cartesian Therapeutics has the GF Score of 16, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Cartesian Therapeutics
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Cartesian Therapeutics GF Score Related Terms
RNAC vs LYEL, ALXO, ARMP: GF Score Comparison
For the Biotechnology subindustry, Cartesian Therapeutics's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cartesian Therapeutics GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cartesian Therapeutics's GF Score distribution charts can be found below:
* The bar in red indicates where Cartesian Therapeutics's GF Score falls into.
Cartesian Therapeutics (RNAC) has a GF Score of 16 as of Jul. 11, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Cartesian Therapeutics and its competitors. This is 64% below median its historical median of 45.00. Over the past decade, Cartesian Therapeutics' GF Score has ranged from 10.00 to 72.00.
Is Cartesian Therapeutics' GF Score too high?
Cartesian Therapeutics' current GF Score of 16 is 64% below median its 10-year median of 45.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 72.00. Overall, Cartesian Therapeutics has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cartesian Therapeutics' GF Score compare to LYEL and ALXO?
Cartesian Therapeutics' GF Score of 16 can be compared against companies in the Biotechnology industry. Historically, Cartesian Therapeutics' own GF Score has ranged from 10.00 to 72.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Cartesian Therapeutics and its competitors. Cartesian Therapeutics's current GF Score is 16, which is 64% below median its own 10-year median of 45.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cartesian Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cartesian Therapeutics (RNAC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $9.49 — trading 3289.3% above its estimated fair value. The current GF Score is 16, which is 64% below median its 10-year median of 45.00. Cartesian Therapeutics' overall GF Score™ is 16/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Cartesian Therapeutics (RNAC), the current GF Score is 16 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cartesian Therapeutics (RNAC) Overvalued in 2026?
Based on GuruFocus' analysis, Cartesian Therapeutics stock appears to be overvalued.
The current stock price of $9.49 is trading 3289.3% above its estimated GF Value™ of $0.28.
GuruFocus considers Cartesian Therapeutics to be Significantly Overvalued.
Key valuation signals for RNAC:
GF Score: 16 (64% below median its 10-year median of 45.00)
GF Value™: $0.28 vs. price of $9.49 (3289.3% above fair value)
No single metric tells the full story. See the RNAC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering cell therapy for the treatment of autoimmune diseases. The company uses technology and a manufacturing platform to introduce mRNA into cells to provide a therapeutic effect to patients suffering from a variety of autoimmune conditions. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material.
16GF Score
Get the complete analysis for RNAC
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNAC has been successfully added to your 